Clinical Trial

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

Study acronym: CANTAB

Active, Not Recruiting

Record status

This record was last updated April 24, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Summary

Cognitive impairments in cancer patients represent an important clinical problem. Studies to date estimating prevalence of difficulties in memory, executive function, and attention deficits have been limited by small sample sizes and many have lacked healthy control groups. More information is needed on promising biomarkers and allelic variants that may help to determine the etiology of impairment, identify those most vulnerable to impairment, and develop interventions for these difficulties. This is a longitudinal observational study of cognitive function in breast cancer and lymphoma patients receiving chemotherapy to better understand the prevalence of cognitive difficulties (i.e., problems with memory, executive function, and attention) in these populations.

Protocol Amendment History 1 change

critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-04-25

Trial Details

NCT Number	NCT01382082
Lead Sponsor	University of Rochester NCORP Research Base Collaborators: National Cancer Institute (NCI)
Conditions	Breast Cancer, Lymphoma
Enrollment	1,432 participants
Start Date	2011-07-14
Primary Completion	2026-07-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-24